30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

23
30 patient drug sensitivity data Figure S1

Transcript of 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Page 1: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

30 patient drug sensitivity data

Figure S1

Page 2: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2AMyeloid regulator enrichment in AML

Page 3: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2BMyeloid regulator enrichment in cALL

Page 4: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2CMyeloid regulator enrichment in CLL

Page 5: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2DMyeloid regulator enrichment in MDS

Page 6: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3AMalacards AML

Page 7: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3BMalacards cALL

Page 8: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3CMalacards CLL

Page 9: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3DMalacards MDS

Page 10: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4ACGC AML

Page 11: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4BCGC cALL

Page 12: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4CCGC CLL

Page 13: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4DCGC MDS

Page 14: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S5

Page 15: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S6

Page 16: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S7

Page 17: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S8Apoptosis AML

Page 18: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Signal transduction

Immune response

Mitochondrial function

Celluar cytoskeletonHeme biosynthesis

Figure S9

Page 19: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

BCL-2

BAX

Known anti-apoptotic factors

A key mitochondrial pro-apoptotic protein

Ohtsuka et al (2004)

PYCARD Apoptosis SER in AML

A key mediator in apoptosis and inflammation

Youle et al (2008)

FIGURE S10

Page 20: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S11

Page 21: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S12

Page 22: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S13

Page 23: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S14